LZTS2 antibody (C-Term)
Quick Overview for LZTS2 antibody (C-Term) (ABIN1450155)
Target
See all LZTS2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Purification
- Affinity chromatography purified via peptide column
-
Immunogen
- A 17 amino acid synthetic peptide near the carboxy terminus of Human LZTS2
-
Isotype
- IgG
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- LZTS2 (Leucine Zipper, Putative Tumor Suppressor 2 (LZTS2))
-
Alternative Name
- LZTS2
-
Background
- The leucine zipper putative tumor suppressor 2 (LZTS2, also known as LAPSER1), a member of the LZTS family, is a negative regulator of the Wnt signaling pathway. It represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin. LZTS2 is involved in cytokinesis and regulates katanin-mediated microtubule severing and release from the centrosome. LZTS2 may negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. LZTS2 is highly expressed in testis and prostate, but it is deleted in multiple cancers, including prostate tumors, suggesting that LZTS2 acts as a potential tumor suppressor.Synonyms: KIAA1813, LAPSER1, LZTS2, Leucine zipper putative tumor suppressor 2, hLZTS2
-
Gene ID
- 84445
-
NCBI Accession
- NP_115805
Target
-